Cargando…

Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms

Detalles Bibliográficos
Autores principales:	Gegenava, Maka, Beaart, Hannelore Jacqueline Lucia, Monahan, Rory Caitlin, Brilman, Elisabeth, Beaart-van de Voorde, Liesbeth J J, Magro-Checa, Cesar, Huizinga, Tom W J, Steup-Beekman, Gerda M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Lupus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560656/ https://www.ncbi.nlm.nih.gov/pubmed/31245049 http://dx.doi.org/10.1136/rmdopen-2019-000895

Ejemplares similares

White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms
por: Monahan, Rory Caitlin, et al.
Publicado: (2021)

Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations
por: Monahan, Rory C, et al.
Publicado: (2022)

Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort
por: Magro-Checa, C., et al.
Publicado: (2018)

Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life
por: Monahan, R C, et al.
Publicado: (2017)

Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in an academic tertiary care centre
por: Schmidtmann, Irene, et al.
Publicado: (2023)

Dissociation in SLE: A part of lupus fog?
por: Monahan, Rory C, et al.
Publicado: (2021)

Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective
por: Pons-Estel, Guillermo J, et al.
Publicado: (2020)

Suspected Transverse Myelitis with Normal MRI and CSF Findings in a Patient with Lupus: What to Do? A Case Series and Systematic Review
por: Monahan, Rory C, et al.
Publicado: (2020)

Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity
por: Monahan, Rory C, et al.
Publicado: (2021)

Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases
por: Flint, Shaun M, et al.
Publicado: (2016)

Standardised incidence ratios (SIRs) for cancer after renal transplant in systemic lupus erythematosus (SLE) and non-SLE recipients
por: Ramsey-Goldman, Rosalind, et al.
Publicado: (2016)

Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study
por: Monahan, Rory C, et al.
Publicado: (2023)

Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease
por: Magallares, Berta, et al.
Publicado: (2021)

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
por: Arkema, Elizabeth V., et al.
Publicado: (2016)

Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands
por: Monahan, Rory C, et al.
Publicado: (2020)

Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives
por: Magro-Checa, César, et al.
Publicado: (2016)

p16(Ink4a), a marker of cellular senescence, is associated with renal disease in the B6.NZMSle1/Sle2/Sle3 mouse model of lupus
por: Tilman, Gaëlle, et al.
Publicado: (2023)

Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis
por: Wang, Huijing, et al.
Publicado: (2021)

Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study
por: Anderson, Meghan, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE
por: Xie, Han, et al.
Publicado: (2023)

Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations
por: Kostopoulou, Myrto, et al.
Publicado: (2020)

Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE
por: Cody, Ellen M, et al.
Publicado: (2023)

Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA
por: Brunner, Hermine I, et al.
Publicado: (2023)

Epigenetics in SLE
por: Hedrich, Christian Michael
Publicado: (2017)

Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease
por: Yavuz, Sule, et al.
Publicado: (2022)

Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis
por: Boedigheimer, Michael J, et al.
Publicado: (2017)

Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study
por: Wahadat, Mohamed Javad, et al.
Publicado: (2023)

Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI
por: Inglese, Francesca, et al.
Publicado: (2021)

Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go?
por: Magro-Checa, César, et al.
Publicado: (2018)

Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?—observations from the UK JSLE Cohort Study
por: Smith, Eve M D, et al.
Publicado: (2021)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity
por: Panousis, Nikolaos I, et al.
Publicado: (2019)

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations
por: Drosos, George C, et al.
Publicado: (2023)

A Review of Complement Activation in SLE
por: Weinstein, Arthur, et al.
Publicado: (2021)

Use of SIICC / ACR damage index in adolescents with SLE
por: Bogmat, Ludmila, et al.
Publicado: (2014)

Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
por: Deonaraine, Kristina K, et al.
Publicado: (2021)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study
por: Ishii, Sho, et al.
Publicado: (2015)

Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE)
por: Mulvihill, Evan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iq3urkj56b6ujo9gbl8vs1tc34